All In MedTech

Device Trial Radar · NCT05042453

Long-term Evaluation of the Efficacy and Safety of Splentis for the Treatment of Primary Apical Pelvic Organ Prolapse

Prospective, Multicenter, 60 Months, Single-arm Cohort Trial for Evaluation of the Efficacy and Safety of Transvaginal Sacrospinous Ligament Fixation With Splentis for the Treatment of Primary Apical Pelvic Organ Prolapse

Last checked: Nov 20, 2026Latest source record: Nov 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Dec 19, 2022

Primary completion

Jul 2026

Study completion Jul 2030

Sponsor

Lead sponsor
PromedonNot on our public-company list
Sponsor type
Industry
First posted
Sep 13, 2021

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This prospective, multi center cohort trial aims to evaluate the efficacy and safety of hysteropexy using Splentis via the vaginal route in primary uterine prolapse

Conditions

  • Pelvic Organ Prolapse

Interventions

  • Splentis® POP Tissue Anchoring SystemDevice

    Anterior cervicopexy with bilateral sacrospinous ligament fixation using Splentis

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cure of apical pelvic organ prolapseTime frame: 12 months

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • DRK Hospital Chemnitz-Rabenstein

    Chemnitz, Germany · Recruiting

  • Helios Hospital Erfurt, Department of gynaecology

    Erfurt, Germany · Recruiting

  • University Hospital Freiburg

    Freiburg im Breisgau, Germany · Recruiting

4 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.